Antiplatelet Therapy Monitoring in Neonates and Children

Joanna Yilin Huang, Diajeng Ayesha Soeharto, Ivan Damara, Vera Ignjatovic, Matthew D. Linden, Paul Monagle

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Antiplatelet agents are used for the prevention and treatment of thromboembolic disease in an increasingly complex population of pediatric patients. Despite their importance for clinical outcome, there is no consensus on the most effective monitoring strategies. This review describes the current state of knowledge focusing on antiplatelet therapy monitoring in children. The authors searched five databases (PubMed-NCBI, MEDLINE-OVID, SCOPUS-Elsevier, ScienceDirect, and Cochrane) from January 2000 to October 2017 using keywords selected a priori . Identified articles were sorted according to the antiplatelet agents administered, methods of antiplatelet monitoring, and outcome measures. Twenty studies were included, with 14 cohort studies, 3 randomized controlled trials, and 3 cross-sectional studies. Eleven different antiplatelet monitoring tools were used, with the most common being Light Transmission Aggregometry, Urinary Thromboxane, Thromboelastography with Platelet Mapping, and VerifyNow. In the majority of studies, antiplatelet therapy monitoring was used to describe adequacy or responsiveness to treatment based on laboratory cut-off values, which were not uniform and sourced from adult studies or extrapolated from test manuals. Several studies evaluated monitoring related to clinical outcome or adjusted therapy to reach predefined therapeutic targets. There was no single laboratory method found to be distinctly better for monitoring antiplatelet treatment. Associations between laboratory assays and clinical outcomes or assays and gold standard measurements were highly inconsistent. The current literature lacks consensus on clinical benefits and measurable effects of monitoring antiplatelet therapy in pediatric patients. This review highlights important areas for research required to determine the value of antiplatelet therapy monitoring in children.

Original languageEnglish
Pages (from-to)73-85
Number of pages13
JournalSeminars in Thrombosis and Hemostasis
Volume45
Issue number1
DOIs
Publication statusPublished - Feb 2019

Cite this

Huang, J. Y., Soeharto, D. A., Damara, I., Ignjatovic, V., Linden, M. D., & Monagle, P. (2019). Antiplatelet Therapy Monitoring in Neonates and Children. Seminars in Thrombosis and Hemostasis, 45(1), 73-85. https://doi.org/10.1055/s-0038-1676375
Huang, Joanna Yilin ; Soeharto, Diajeng Ayesha ; Damara, Ivan ; Ignjatovic, Vera ; Linden, Matthew D. ; Monagle, Paul. / Antiplatelet Therapy Monitoring in Neonates and Children. In: Seminars in Thrombosis and Hemostasis. 2019 ; Vol. 45, No. 1. pp. 73-85.
@article{61069c48b06148838e15fe113cf04df1,
title = "Antiplatelet Therapy Monitoring in Neonates and Children",
abstract = "Antiplatelet agents are used for the prevention and treatment of thromboembolic disease in an increasingly complex population of pediatric patients. Despite their importance for clinical outcome, there is no consensus on the most effective monitoring strategies. This review describes the current state of knowledge focusing on antiplatelet therapy monitoring in children. The authors searched five databases (PubMed-NCBI, MEDLINE-OVID, SCOPUS-Elsevier, ScienceDirect, and Cochrane) from January 2000 to October 2017 using keywords selected a priori . Identified articles were sorted according to the antiplatelet agents administered, methods of antiplatelet monitoring, and outcome measures. Twenty studies were included, with 14 cohort studies, 3 randomized controlled trials, and 3 cross-sectional studies. Eleven different antiplatelet monitoring tools were used, with the most common being Light Transmission Aggregometry, Urinary Thromboxane, Thromboelastography with Platelet Mapping, and VerifyNow. In the majority of studies, antiplatelet therapy monitoring was used to describe adequacy or responsiveness to treatment based on laboratory cut-off values, which were not uniform and sourced from adult studies or extrapolated from test manuals. Several studies evaluated monitoring related to clinical outcome or adjusted therapy to reach predefined therapeutic targets. There was no single laboratory method found to be distinctly better for monitoring antiplatelet treatment. Associations between laboratory assays and clinical outcomes or assays and gold standard measurements were highly inconsistent. The current literature lacks consensus on clinical benefits and measurable effects of monitoring antiplatelet therapy in pediatric patients. This review highlights important areas for research required to determine the value of antiplatelet therapy monitoring in children.",
keywords = "antiplatelet therapy, monitoring, child, therapy, prevention, ASPIRIN RESISTANCE, PLATELET INHIBITION, CLOPIDOGREL, RISK, INFANTS, EVENTS, AGGREGOMETRY, PREVALENCE, REACTIVITY, THROMBOSIS",
author = "Huang, {Joanna Yilin} and Soeharto, {Diajeng Ayesha} and Ivan Damara and Vera Ignjatovic and Linden, {Matthew D.} and Paul Monagle",
year = "2019",
month = "2",
doi = "10.1055/s-0038-1676375",
language = "English",
volume = "45",
pages = "73--85",
journal = "Seminars in Thrombosis and Hemostasis",
issn = "0094-6176",
publisher = "THIEME MEDICAL PUBL INC",
number = "1",

}

Huang, JY, Soeharto, DA, Damara, I, Ignjatovic, V, Linden, MD & Monagle, P 2019, 'Antiplatelet Therapy Monitoring in Neonates and Children' Seminars in Thrombosis and Hemostasis, vol. 45, no. 1, pp. 73-85. https://doi.org/10.1055/s-0038-1676375

Antiplatelet Therapy Monitoring in Neonates and Children. / Huang, Joanna Yilin; Soeharto, Diajeng Ayesha; Damara, Ivan; Ignjatovic, Vera; Linden, Matthew D.; Monagle, Paul.

In: Seminars in Thrombosis and Hemostasis, Vol. 45, No. 1, 02.2019, p. 73-85.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antiplatelet Therapy Monitoring in Neonates and Children

AU - Huang, Joanna Yilin

AU - Soeharto, Diajeng Ayesha

AU - Damara, Ivan

AU - Ignjatovic, Vera

AU - Linden, Matthew D.

AU - Monagle, Paul

PY - 2019/2

Y1 - 2019/2

N2 - Antiplatelet agents are used for the prevention and treatment of thromboembolic disease in an increasingly complex population of pediatric patients. Despite their importance for clinical outcome, there is no consensus on the most effective monitoring strategies. This review describes the current state of knowledge focusing on antiplatelet therapy monitoring in children. The authors searched five databases (PubMed-NCBI, MEDLINE-OVID, SCOPUS-Elsevier, ScienceDirect, and Cochrane) from January 2000 to October 2017 using keywords selected a priori . Identified articles were sorted according to the antiplatelet agents administered, methods of antiplatelet monitoring, and outcome measures. Twenty studies were included, with 14 cohort studies, 3 randomized controlled trials, and 3 cross-sectional studies. Eleven different antiplatelet monitoring tools were used, with the most common being Light Transmission Aggregometry, Urinary Thromboxane, Thromboelastography with Platelet Mapping, and VerifyNow. In the majority of studies, antiplatelet therapy monitoring was used to describe adequacy or responsiveness to treatment based on laboratory cut-off values, which were not uniform and sourced from adult studies or extrapolated from test manuals. Several studies evaluated monitoring related to clinical outcome or adjusted therapy to reach predefined therapeutic targets. There was no single laboratory method found to be distinctly better for monitoring antiplatelet treatment. Associations between laboratory assays and clinical outcomes or assays and gold standard measurements were highly inconsistent. The current literature lacks consensus on clinical benefits and measurable effects of monitoring antiplatelet therapy in pediatric patients. This review highlights important areas for research required to determine the value of antiplatelet therapy monitoring in children.

AB - Antiplatelet agents are used for the prevention and treatment of thromboembolic disease in an increasingly complex population of pediatric patients. Despite their importance for clinical outcome, there is no consensus on the most effective monitoring strategies. This review describes the current state of knowledge focusing on antiplatelet therapy monitoring in children. The authors searched five databases (PubMed-NCBI, MEDLINE-OVID, SCOPUS-Elsevier, ScienceDirect, and Cochrane) from January 2000 to October 2017 using keywords selected a priori . Identified articles were sorted according to the antiplatelet agents administered, methods of antiplatelet monitoring, and outcome measures. Twenty studies were included, with 14 cohort studies, 3 randomized controlled trials, and 3 cross-sectional studies. Eleven different antiplatelet monitoring tools were used, with the most common being Light Transmission Aggregometry, Urinary Thromboxane, Thromboelastography with Platelet Mapping, and VerifyNow. In the majority of studies, antiplatelet therapy monitoring was used to describe adequacy or responsiveness to treatment based on laboratory cut-off values, which were not uniform and sourced from adult studies or extrapolated from test manuals. Several studies evaluated monitoring related to clinical outcome or adjusted therapy to reach predefined therapeutic targets. There was no single laboratory method found to be distinctly better for monitoring antiplatelet treatment. Associations between laboratory assays and clinical outcomes or assays and gold standard measurements were highly inconsistent. The current literature lacks consensus on clinical benefits and measurable effects of monitoring antiplatelet therapy in pediatric patients. This review highlights important areas for research required to determine the value of antiplatelet therapy monitoring in children.

KW - antiplatelet therapy

KW - monitoring

KW - child

KW - therapy

KW - prevention

KW - ASPIRIN RESISTANCE

KW - PLATELET INHIBITION

KW - CLOPIDOGREL

KW - RISK

KW - INFANTS

KW - EVENTS

KW - AGGREGOMETRY

KW - PREVALENCE

KW - REACTIVITY

KW - THROMBOSIS

U2 - 10.1055/s-0038-1676375

DO - 10.1055/s-0038-1676375

M3 - Article

VL - 45

SP - 73

EP - 85

JO - Seminars in Thrombosis and Hemostasis

JF - Seminars in Thrombosis and Hemostasis

SN - 0094-6176

IS - 1

ER -